Case Study 2: transforming a toxin into a therapeutic

the sea anemone potassium channel blocker ShK toxin for treatment of autoimmune diseases

Raymond Norton, Michael W. Pennington, Christine Beeton

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

Abstract

Diseases with an autoimmune component can affect virtually any organ in the body, and they currently afflict millions of people worldwide. These chronic disorders are oen diagnosed in young adults, or even children, and they can be debilitating and lead to premature death. Immunomodulators such as methotrexate, monoclonal antibodies (natalizumab, inflximab), glatiramer acetate, mitoxantrone, tumour necrosis factor antagonists (etanercept, infliximab) and steroids have considerably improved the management of autoimmune diseases, but they can cause generalized immunosuppression and therefore put patients at an increased risk of tumour cell proliferation or opportunistic infections. Kv1.3 channel blockers represent a new class of immunomodulators with a lower risk of inducing generalized immunosuppression as they preferentially target the effectormemory T (TEM) lymphocytes involved in autoimmune diseases, with little or no effect on other subsets of lymphocytes.
Original languageEnglish
Title of host publicationVenoms to Drugs
Subtitle of host publicationVenom as a Source for the Development of Human Therapeutics
EditorsGlenn F. King
Place of PublicationCambridge UK
PublisherThe Royal Society of Chemistry
Pages255-274
Number of pages20
Volume2015-January
ISBN (Electronic)978-1-84973-787-6
ISBN (Print)978-1-84973-663-3
DOIs
Publication statusPublished - 2015

Publication series

NameRSC Drug Discovery Series
PublisherThe Royal Society of Chemistry
Number42
ISSN (Print)2041-3203

Cite this

Norton, R., Pennington, M. W., & Beeton, C. (2015). Case Study 2: transforming a toxin into a therapeutic: the sea anemone potassium channel blocker ShK toxin for treatment of autoimmune diseases. In G. F. King (Ed.), Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics (Vol. 2015-January, pp. 255-274). (RSC Drug Discovery Series; No. 42). Cambridge UK: The Royal Society of Chemistry. https://doi.org/10.1039/9781849737876-00255
Norton, Raymond ; Pennington, Michael W. ; Beeton, Christine. / Case Study 2: transforming a toxin into a therapeutic : the sea anemone potassium channel blocker ShK toxin for treatment of autoimmune diseases. Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics. editor / Glenn F. King. Vol. 2015-January Cambridge UK : The Royal Society of Chemistry, 2015. pp. 255-274 (RSC Drug Discovery Series; 42).
@inbook{2a4360bb47ab4c609b0aed0bd4f4ea51,
title = "Case Study 2: transforming a toxin into a therapeutic: the sea anemone potassium channel blocker ShK toxin for treatment of autoimmune diseases",
abstract = "Diseases with an autoimmune component can affect virtually any organ in the body, and they currently afflict millions of people worldwide. These chronic disorders are oen diagnosed in young adults, or even children, and they can be debilitating and lead to premature death. Immunomodulators such as methotrexate, monoclonal antibodies (natalizumab, inflximab), glatiramer acetate, mitoxantrone, tumour necrosis factor antagonists (etanercept, infliximab) and steroids have considerably improved the management of autoimmune diseases, but they can cause generalized immunosuppression and therefore put patients at an increased risk of tumour cell proliferation or opportunistic infections. Kv1.3 channel blockers represent a new class of immunomodulators with a lower risk of inducing generalized immunosuppression as they preferentially target the effectormemory T (TEM) lymphocytes involved in autoimmune diseases, with little or no effect on other subsets of lymphocytes.",
author = "Raymond Norton and Pennington, {Michael W.} and Christine Beeton",
year = "2015",
doi = "10.1039/9781849737876-00255",
language = "English",
isbn = "978-1-84973-663-3",
volume = "2015-January",
series = "RSC Drug Discovery Series",
publisher = "The Royal Society of Chemistry",
number = "42",
pages = "255--274",
editor = "King, {Glenn F. }",
booktitle = "Venoms to Drugs",

}

Norton, R, Pennington, MW & Beeton, C 2015, Case Study 2: transforming a toxin into a therapeutic: the sea anemone potassium channel blocker ShK toxin for treatment of autoimmune diseases. in GF King (ed.), Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics. vol. 2015-January, RSC Drug Discovery Series, no. 42, The Royal Society of Chemistry, Cambridge UK, pp. 255-274. https://doi.org/10.1039/9781849737876-00255

Case Study 2: transforming a toxin into a therapeutic : the sea anemone potassium channel blocker ShK toxin for treatment of autoimmune diseases. / Norton, Raymond; Pennington, Michael W.; Beeton, Christine.

Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics. ed. / Glenn F. King. Vol. 2015-January Cambridge UK : The Royal Society of Chemistry, 2015. p. 255-274 (RSC Drug Discovery Series; No. 42).

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

TY - CHAP

T1 - Case Study 2: transforming a toxin into a therapeutic

T2 - the sea anemone potassium channel blocker ShK toxin for treatment of autoimmune diseases

AU - Norton, Raymond

AU - Pennington, Michael W.

AU - Beeton, Christine

PY - 2015

Y1 - 2015

N2 - Diseases with an autoimmune component can affect virtually any organ in the body, and they currently afflict millions of people worldwide. These chronic disorders are oen diagnosed in young adults, or even children, and they can be debilitating and lead to premature death. Immunomodulators such as methotrexate, monoclonal antibodies (natalizumab, inflximab), glatiramer acetate, mitoxantrone, tumour necrosis factor antagonists (etanercept, infliximab) and steroids have considerably improved the management of autoimmune diseases, but they can cause generalized immunosuppression and therefore put patients at an increased risk of tumour cell proliferation or opportunistic infections. Kv1.3 channel blockers represent a new class of immunomodulators with a lower risk of inducing generalized immunosuppression as they preferentially target the effectormemory T (TEM) lymphocytes involved in autoimmune diseases, with little or no effect on other subsets of lymphocytes.

AB - Diseases with an autoimmune component can affect virtually any organ in the body, and they currently afflict millions of people worldwide. These chronic disorders are oen diagnosed in young adults, or even children, and they can be debilitating and lead to premature death. Immunomodulators such as methotrexate, monoclonal antibodies (natalizumab, inflximab), glatiramer acetate, mitoxantrone, tumour necrosis factor antagonists (etanercept, infliximab) and steroids have considerably improved the management of autoimmune diseases, but they can cause generalized immunosuppression and therefore put patients at an increased risk of tumour cell proliferation or opportunistic infections. Kv1.3 channel blockers represent a new class of immunomodulators with a lower risk of inducing generalized immunosuppression as they preferentially target the effectormemory T (TEM) lymphocytes involved in autoimmune diseases, with little or no effect on other subsets of lymphocytes.

UR - http://www.scopus.com/inward/record.url?scp=84937405346&partnerID=8YFLogxK

U2 - 10.1039/9781849737876-00255

DO - 10.1039/9781849737876-00255

M3 - Chapter (Book)

SN - 978-1-84973-663-3

VL - 2015-January

T3 - RSC Drug Discovery Series

SP - 255

EP - 274

BT - Venoms to Drugs

A2 - King, Glenn F.

PB - The Royal Society of Chemistry

CY - Cambridge UK

ER -

Norton R, Pennington MW, Beeton C. Case Study 2: transforming a toxin into a therapeutic: the sea anemone potassium channel blocker ShK toxin for treatment of autoimmune diseases. In King GF, editor, Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics. Vol. 2015-January. Cambridge UK: The Royal Society of Chemistry. 2015. p. 255-274. (RSC Drug Discovery Series; 42). https://doi.org/10.1039/9781849737876-00255